主要肿瘤抑制因子与致癌性非编码RNA:在肺癌中的临床相关性
Major Tumor Suppressor and Oncogenic Non-Coding RNAs: Clinical Relevance in Lung Cancer.
作者信息
Inamura Kentaro
机构信息
Division of Pathology, The Cancer Institute, Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo 135-8550, Japan.
出版信息
Cells. 2017 May 9;6(2):12. doi: 10.3390/cells6020012.
Lung cancer is the leading cause of cancer deaths worldwide, yet there remains a lack of specific and sensitive tools for early diagnosis and targeted therapies. High-throughput sequencing techniques revealed that non-coding RNAs (ncRNAs), e.g., microRNAs and long ncRNAs (lncRNAs), represent more than 80% of the transcribed human genome. Emerging evidence suggests that microRNAs and lncRNAs regulate target genes and play an important role in biological processes and signaling pathways in malignancies, including lung cancer. In lung cancer, several tumor suppressor/oncogenic microRNAs and lncRNAs function as biomarkers for metastasis and prognosis, and thus may serve as therapeutic tools. In this review, recent work on microRNAs and lncRNAs is introduced and briefly summarized with a focus on potential biological and therapeutic applications.
肺癌是全球癌症死亡的主要原因,但仍然缺乏用于早期诊断和靶向治疗的特异性和敏感性工具。高通量测序技术表明,非编码RNA(ncRNA),如微小RNA和长链非编码RNA(lncRNA),占人类转录基因组的80%以上。新出现的证据表明,微小RNA和lncRNA可调节靶基因,并在包括肺癌在内的恶性肿瘤的生物学过程和信号通路中发挥重要作用。在肺癌中,几种抑癌/致癌微小RNA和lncRNA可作为转移和预后的生物标志物,因此可能用作治疗工具。在本综述中,将介绍并简要总结关于微小RNA和lncRNA的最新研究工作,重点关注其潜在的生物学和治疗应用。